Advertisement
Advertisement
U.S. Markets closed
S&P Futures
3,898.75 -17.50 (-0.45%) Dow Futures
31,352.00 -135.00 (-0.43%) Nasdaq Futures
12,090.00 -50.50 (-0.42%) Russell 2000 Futures
1,753.10 -8.60 (-0.49%) Crude Oil
106.10 -1.52 (-1.41%) Gold
1,831.70 +1.40 (+0.08%)
Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 607.39 |
| Open | 612.06 |
| Bid | 612.61 x 800 |
| Ask | 614.99 x 800 |
| Day's Range | 602.52 - 613.15 |
| 52 Week Range | 536.08 - 747.42 |
| Volume | |
| Avg. Volume | 713,509 |
| Market Cap | 65.869B |
| Beta (5Y Monthly) | 0.21 |
| PE Ratio (TTM) | 9.80 |
| EPS (TTM) | 62.53 |
| Earnings Date | Feb 03, 2022 - Feb 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 702.05 |
- Motley Fool
Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA
Mega-blockbuster Dupixent was just given the FDA's green light to treat patients with a chronic, progressive inflammatory disease.
- Zacks
Regeneron (REGN) Gains But Lags Market: What You Should Know
Regeneron (REGN) closed at $612.49 in the latest trading session, marking a +0.84% move from the prior day.
- Benzinga
Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis
Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced additional interim data from the Phase 1 study of NTLA-2001, in vivo genome editing candidate for transthyretin (ATTR) amyloidosis. Intellia had said that at the highest dose level (1.0mg/kg), six patients had shown a 93% mean reduction in the toxic protein. In the new data, three patients reached the nine-month follow-up point and maintained that level of TTR reduction. Related: Intellia Shares U
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
